Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of BR9003 vs BR9003A in Healthy Adults
NCT04857047Phase 1Completed
- Sponsor
- Boryung
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of varenicline in nicotine dependence (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Concentration-Time Curve from 0 to 24 hours at Steady State and Maximum Plasma Concentration at Steady State. Started Mar 2021; status: completed.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT04857047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857047.